Get the Stockscreener App
7.09
0.14%
0.010
Arvinas Inc stock is traded at $7.09, with a volume of 1.43M.
It is up +0.14% in the last 24 hours and down -4.19% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$7.08
Open:
$7.16
24h Volume:
1.43M
Relative Volume:
0.70
Market Cap:
$520.53M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-1.5182
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
+12.72%
1M Performance:
-4.19%
6M Performance:
-61.28%
1Y Performance:
-72.30%
1-Day Range:
$6.96
$7.26
1-Week Range:
$6.32
$7.29
52-Week Range:
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.09 | 519.80M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Is Arvinas Inc. a speculative investmentMarket Movers & Daily Risk Controlled Trade Plans - thegnnews.com
FY2025 EPS Estimates for Arvinas Cut by Cantor Fitzgerald - MarketBeat
Can Arvinas Inc. scale operations efficientlyJuly 2025 Spike Watch & Free Safe Entry Trade Signal Reports - classian.co.kr
HC Wainwright Comments on Arvinas' Q3 Earnings (NASDAQ:ARVN) - MarketBeat
Leerink Partnrs Analysts Cut Earnings Estimates for Arvinas - MarketBeat
Wedbush Has Optimistic Outlook of Arvinas Q3 Earnings - MarketBeat
Will Arvinas Inc. stock go up soon2025 Retail Activity & High Accuracy Trade Signal Alerts - Newser
Will Arvinas Inc. stock benefit from AI tech trendsForecast Cut & Advanced Swing Trade Entry Plans - Newser
Arvinas’s SWOT analysis: protein degrader stock faces pivotal moment By Investing.com - Investing.com Nigeria
Arvinas’s SWOT analysis: protein degrader stock faces pivotal moment - Investing.com
How institutional ownership impacts Arvinas Inc. stockTake Profit & Daily Growth Stock Investment Tips - Newser
Arvinas, Inc. (NASDAQ:ARVN) Receives $19.76 Consensus PT from Analysts - MarketBeat
Custom watchlist performance reports with Arvinas Inc.Take Profit & Capital Efficiency Focused Ideas - Newser
Using data filters to optimize entry into Arvinas Inc.Fundamental + Technical Combined Watchlist - Newser
Arvinas (NASDAQ:ARVN) Given New $15.00 Price Target at Guggenheim - MarketBeat
Arvinas (NASDAQ:ARVN) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
HC Wainwright Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Is Arvinas Inc. Stock a Good Fit for Conservative InvestorsFree Real Time Stock Movement Analysis - Newser
Metastatic Prostate Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion - Barchart.com
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer - Yahoo Finance
Wedbush Issues Positive Forecast for Arvinas Earnings - Defense World
Arvinas (NASDAQ:ARVN) Price Target Cut to $16.00 by Analysts at Wells Fargo & Company - MarketBeat
HC Wainwright Comments on Arvinas’ Q3 Earnings (NASDAQ:ARVN) - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by XTX Topco Ltd - MarketBeat
Wells Fargo & Company Cuts Arvinas (NASDAQ:ARVN) Price Target to $16.00 - Defense World
What Fibonacci levels say about Arvinas Inc. reboundSector Rotation Strategy for Smart Traders - Newser
Arvinas and Pfizer’s FDA Nod for Cancer Drug - The Globe and Mail
Arvinas, Inc. (NASDAQ:ARVN) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - 富途牛牛
Arvinas, Inc. (NASDAQ:ARVN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
FDA Accepts Arvinas, Pfizer's Vepdegestrant NDA for Breast Cancer Treatment - AInvest
FDA to Review Pfizer and Arvinas' Breast Cancer Therapy Vepdegestrant by June 5, 2026. - AInvest
Arvinas' Breakthrough in PROTACs: A Catalyst for Valuation Re-Rating in Oncology's New Frontier - AInvest
Arvinas Q2 2025 Earnings: Revenue Down, Clinical Progress & New CEO Announcement - AInvest
Arvinas, Pfizer announce FDA acceptance of vepdegestrant NDA - TipRanks
Arvinas and Pfizer Announce FDA Acceptance of NDA for Vepdegestrant Following Positive Phase 3 VERITAC-2 Trial Results in Advanced Breast Cancer - Quiver Quantitative
Arvinas Announces FDA Acceptance of the New Drug - GlobeNewswire
ARVNArvinas Latest Stock News & Market Updates - Stock Titan
Arvinas Holding Company (ARVN) Gets a Buy from Guggenheim - The Globe and Mail
Arvinas Holding’s Strategic Uncertainties and Partnership Challenges Justify Hold Rating - TipRanks
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $9 to $18 - 富途牛牛
Arvinas (ARVN) Shares Plunge 2.95% to 2025 Low Amid Mixed Clinical Results and Partnership Uncertainty - AInvest
Arvinas 2025 Q2 Earnings Record Net Income Despite Worsening Losses - AInvest
Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug - BioPharma Dive
Arvinas signals CEO transition and extends cash runway into H2 2028 amid vepdeg collaboration changes - MSN
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach - Stocktwits
Wedbush Cuts Price Target on Arvinas to $10 From $12, Keeps Neutral Rating - MarketScreener
Arvinas price target raised to $24 from $18 at H.C. Wainwright - TipRanks
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $16 to $18 - 富途牛牛
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):